BAALC Gene Expression Detection for Acute Leukemia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and prognosis methods face challenges in accurately detecting genetic changes and predicting the aggressiveness of leukemias, CNS, and prostate cancers, leading to delayed detection and suboptimal therapy selection.
Innovation Solution
Identification of the BAALC gene, which is overexpressed in subsets of leukemias, CNS cancers, and prostate cancer, using oligonucleotides, polynucleotides, antibodies, and peptide immunogens to detect BAALC expression and overexpression in biological samples, enabling characterization and diagnosis of these cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional cytogenetic methods are used to detect genetic changes in leukemia, then visible chromosomal abnormalities can be identified, but many cases with no visible abnormalities are missed and genetic changes cannot be detected early enough
Solution Approach 1:
The patent replaces traditional mechanical cytogenetic analysis methods with molecular biology techniques (RT-PCR, Northern blotting, in situ hybridization) to detect gene expression changes. This substitution enables detection of early genetic changes at the molecular level before phenotypic changes occur, achieving both high precision and early detection timing
Solution Approach 2:
The patent detects gene expression changes (transcription and translation levels) as preliminary indicators of cancer development. By monitoring BAALC gene expression before visible tumor formation or phenotypic changes, the method enables early intervention and diagnosis at the molecular level
2Adaptability or versatility
If phenotypic or pathological classification is used to identify cancer types, then cancer can be broadly categorized, but it is difficult to predict patient lifespan and select optimal therapy for individual patients
Solution Approach 1:
The patent applies local quality by identifying specific gene expression patterns (BAALC overexpression) that characterize particular subsets of leukemia patients. This allows differentiation of local molecular characteristics within the broader leukemia category, enabling personalized prognosis and therapy selection based on individual gene expression profiles
Solution Approach 2:
The patent uses parameter changes in gene expression levels (specifically BAALC transcript abundance) to stratify patients into different risk groups. By measuring and comparing BAALC expression levels against established thresholds, the method provides quantitative prognostic information that guides individualized therapy decisions
3Reliability
If BAALC gene expression detection methods are implemented, then accurate diagnosis and prognosis of leukemia subsets can be achieved, but additional diagnostic testing and analysis complexity are required
Solution Approach 1:
The patent segments the diagnostic process into distinct molecular biology techniques (RT-PCR for transcript detection, Northern blotting for gene expression analysis, in situ hybridization for spatial localization). Each segmented method targets specific aspects of BAALC expression, allowing comprehensive characterization while maintaining standardized procedural protocols for each technique
Data Source
AI summary
Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression.